Regulatory policies on medicines for psychiatric disorders: Is Europe on target?

British Journal of Psychiatry

Volumn 190, Issue FEB., 2007, Pages 91-93

  Barbui, Corrado ^a,c   Garattini, Silvio ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c OSPEDALE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE;

ACUTE PSYCHOSIS; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG LABELING; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; DRUG WITHDRAWAL; EUROPE; HAMILTON SCALE; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; MENTAL DISEASE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

CLINICAL TRIALS; DRUG APPROVAL; EUROPE; GOVERNMENT AGENCIES; HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS;

EID: 33846982983     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.bp.106.024794     Document Type: Review

References (11)

1. Barbui, C., Guaiana, G. & Garattini, S. (2001) Regulatory issues in Europe. Journal of Clinical Psychopharmacology, 21, 545-548.
2. Barbui, C., Tansella, M. & Garattini, S. (2003) Varying and 'atypical' indications for atypical antipsychotics. Psychopharmacology, 169, 205-206.
3. Council of the European Communities (1993) Council Regulation (EEC) No. 2309/93 of 22 July 1993 laying down community procedures for the authorisation and supervision of medicinal products for the human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products. Official Journal of the European Communities, 214, 1-21.
4. Garattini, S. & Bertete', V. (2001) Adjusting Europe's drug regulation to public health needs. Lancet, 358, 64-67.
5. Garattini, S. & Bertele', V. (2003) Efficacy, safety and cost of new drugs acting on the central nervous system. European Journal of Clinical Pharmacology, 59, 79-84.
6. Garattini, S., Bertele', V. & Li, B. L. (2003) Light and shade in proposed revision of EU drug-regulatory legislation. Lancet, 361, 635-636.
7. Geddes, J. & Goodwill, G. (2001) Bipolar disorder: clinical uncertainty, evidence-based medicine and large-scale randomised trials. British Journal of Psychiatry, 178 (suppl. 41), s191-s194.
8. Kemmler, G., Hummer, M., Widschwendter, C., et al (2005) Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Archives of General Psychiatry, 62, 1305-1312.
9. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209-1223.
10. Moncrieff, J. & Kirsch, I. (2005) Efficacy of antidepressants in adults. BMJ, 331, 155-157.
11. Tansella, M., Thornicroft, G., Barbui, C., et al (2006) Seven criteria for improving effectiveness trials in psychiatry. Psychological Medicine, 36, 711-720.